These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 12449273)

  • 41. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study.
    Christiaens L; Ragot S; Mergy J; Allal J; Macchi L
    Blood Coagul Fibrinolysis; 2008 Apr; 19(3):235-9. PubMed ID: 18388505
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Should we treat all diabetic patients with aspirin in primary prevention?].
    Righetti A; De Moerloose P; Philippe J
    Rev Med Suisse; 2005 Jun; 1(22):1500-4. PubMed ID: 16025889
    [TBL] [Abstract][Full Text] [Related]  

  • 43. AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions.
    Nicolucci A; De Berardis G; Sacco M; Tognoni G
    Eur Heart J; 2007 Aug; 28(16):1925-7. PubMed ID: 17604291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers.
    Mikkelsson J; Eskola M; Nikus K; Karhunen PJ; Niemela K
    Ann Med; 2008; 40(4):296-302. PubMed ID: 18428022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low-dose aspirin for primary prevention of cardiovascular disease.
    Bredie SJ; Wollersheim H; Verheugt FW; Thien T
    Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aspirin resistance or variable response or both?
    Cheng X; Chen WH; Simon DI
    Am J Cardiol; 2006 Nov; 98(10A):11N-17N. PubMed ID: 17097412
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland.
    Rodondi N; Cornuz J; Marques-Vidal P; Butler J; Hayoz D; Pécoud A; Paccaud F; Waeber G; Vollenweider P
    Prev Med; 2008 Feb; 46(2):137-44. PubMed ID: 17904211
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular pharmacology core reviews: aspirin.
    Gaglia MA; Clavijo L
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):505-13. PubMed ID: 24057863
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An intervention to improve secondary prevention of coronary heart disease.
    Bailey TC; Noirot LA; Blickensderfer A; Rachmiel E; Schaiff R; Kessels A; Braverman A; Goldberg A; Waterman B; Dunagan WC
    Arch Intern Med; 2007 Mar; 167(6):586-90. PubMed ID: 17389290
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aspirin for primary prevention of cardiovascular disease (revisited).
    Med Lett Drugs Ther; 2006 Jul; 48(1238):53. PubMed ID: 16841021
    [No Abstract]   [Full Text] [Related]  

  • 52. [Primary prevention of cardiovascular diseases with acetylsalicylic acid].
    Waltering A; Hemkens L; Florack C
    Dtsch Med Wochenschr; 2005 Dec; 130(49):2847-52. PubMed ID: 16317615
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effective platelet inhibition by aspirin and clopidogrel: where are we now?
    Tousoulis D; Briasoulis A; Dhamrait SS; Antoniades C; Stefanadis C
    Heart; 2009 May; 95(10):850-8. PubMed ID: 19401288
    [No Abstract]   [Full Text] [Related]  

  • 54. Aspirin for healthy hearts.
    Ornato J
    Health News; 2001 Jan; 7(1):6. PubMed ID: 11198412
    [No Abstract]   [Full Text] [Related]  

  • 55. Aspirin to prevent strokes: fact or fiction?
    Leifer D
    Health News; 2000 May; 6(5):3. PubMed ID: 10851965
    [No Abstract]   [Full Text] [Related]  

  • 56. [Clinical studies of the effectiveness of aspirin in the prevention of major cardio-cerebrovascular occurrences].
    Mariani M; Biadi O
    Cardiologia; 1995 Dec; 40(12 Suppl 1):423-8. PubMed ID: 8998750
    [No Abstract]   [Full Text] [Related]  

  • 57. [Prevention of myocardial infarct and heart failure in the diabetic].
    Schröder H
    Med Monatsschr Pharm; 2003 Jun; 26(6):209-10. PubMed ID: 12840957
    [No Abstract]   [Full Text] [Related]  

  • 58. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events.
    Terpening C
    J Am Board Fam Med; 2009; 22(1):51-6. PubMed ID: 19124633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aspirin resistance and adverse clinical events in patients with coronary artery disease.
    Chen WH; Cheng X; Lee PY; Ng W; Kwok JY; Tse HF; Lau CP
    Am J Med; 2007 Jul; 120(7):631-5. PubMed ID: 17602938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.